Eli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 07/09/25
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipelineProactive Investors • 07/09/25
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's diseasePRNewsWire • 07/09/25
Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.Barrons • 07/04/25
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales GrowthZacks Investment Research • 07/03/25